DelveInsight’s “Onchomycosis Pipeline Insight 2025” report provides comprehensive insights about 11+ companies and 11+ pipeline drugs in the Onchomycosis pipeline landscape. It covers the Onchomycosis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Onchomycosis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Onchomycosis Pipeline? Click here to explore the therapies and trials making headlines @ Onchomycosis Pipeline Outlook Report

Key Takeaways from the Onchomycosis Pipeline Report

• In September 2025, Vanda Pharmaceuticals announced a study designed to evaluate the safety, tolerability, and efficacy of topically administered VTR-297 solution. The efficacy objectives of the study will be assessed using fungal culture testing, Neutral Red Staining (NRS) microscopy examination, and KOH microscopy examination after 4 weeks of treatment with VTR-297.
• DelveInsight’s Onchomycosis Pipeline report depicts a robust space with 11+ active players working to develop 11+ pipeline therapies for Onchomycosis treatment.
• The leading Onchomycosis Companies such as Blueberry Therapeutics, AmtixBio, Mycovia Pharmaceuticals, Polichem, Onicor, Nihon Nohyaku and others.
• Promising Onchomycosis Therapies such as Tavaborole 5% Topical Solution, MOB015B, Terbinafine HCl, Amorolfine 5%, Amorolfine, and others.

Want to know which companies are leading innovation in Onchomycosis? Dive into the full pipeline insights @ Onchomycosis Clinical Trials Assessment

The Onchomycosis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Onchomycosis Pipeline Report also highlights the unmet needs with respect to the Onchomycosis.

Onchomycosis Overview

Onychomycosis is a fungal infection of the nail, typically caused by dermatophytes, which affects approximately 10% of the US population. The disease can have significant negative consequences for patients, including pain, discomfort, and potential impacts on work and social lives. The primary pathogens responsible for onychomycosis are dermatophytes, such as Trichophyton rubrum, Epidermophyton floccosum, and Trichophyton mentagrophytes. Other organisms, including yeasts like Candida albicans and nondermatophyte molds, can also be implicated. The infection can manifest in various forms, including distal subungual onychomycosis, which is the most common type, characterized by invasion of the nail bed and underside of the nail plate.

Onchomycosis Emerging Drugs Profile

• BB2603: Blueberry Therapeutics

Blueberry is developing a new topical antifungal spray formulation of terbinafine (BB2603‑om) for the treatment of onychomycosis using our nanodelivery platform technology. The aim is to apply the spray directly to the nail, and through enhanced delivery of the active substance through the nail, to match the cure rates of the more effective oral formulations in a topical medicine, without the associated safety concerns. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Onychomycosis.

• ATB-1651: AmtixBio

ATB-1651 is a potential first-in-class drug candidate targeting fungal cell wall components. It is a new drug candidate that acts quickly on virulent fungi, can reliably kill fungi, and reliably suppresses the creation of resistant bacteria. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Onychomycosis.

If you’re tracking ongoing Onchomycosis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Onchomycosis Treatment Drugs

The Onchomycosis Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Onchomycosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Onchomycosis Treatment.
• Onchomycosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Onchomycosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Onchomycosis market.

Onchomycosis Companies

Blueberry Therapeutics, AmtixBio, Mycovia Pharmaceuticals, Polichem, Onicor, Nihon Nohyaku and others.

Onchomycosis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Onchomycosis Products have been categorized under various Molecule types such as,

• Monoclonal antibody
• Small molecule
• Peptide

From emerging drug candidates to competitive intelligence, the Onchomycosis Pipeline Report covers it all – check it out now @ Onchomycosis Market Drivers and Barriers, and Future Perspectives

Scope of the Onchomycosis Pipeline Report

• Coverage- Global
• Onchomycosis Companies- Blueberry Therapeutics, AmtixBio, Mycovia Pharmaceuticals, Polichem, Onicor, Nihon Nohyaku and others.
• Onchomycosis Therapies- Tavaborole 5% Topical Solution, MOB015B, Terbinafine HCl, Amorolfine 5%, Amorolfine, and others.
• Onchomycosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Onchomycosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Onchomycosis Treatment landscape in this detailed analysis @ Onchomycosis Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Onychomycosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Onychomycosis– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. BB2603: Blueberry Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ATB-1651: AmtixBio
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Onychomycosis Key Companies
21. Onychomycosis Key Products
22. Onychomycosis- Unmet Needs
23. Onychomycosis- Market Drivers and Barriers
24. Onychomycosis- Future Perspectives and Conclusion
25. Onychomycosis Analyst Views
26. Onychomycosis Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/onychomycosis-pipeline-insight